Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2020 11 02; 22(1):120.

View in: PubMed

subject areas

Adult
Aged
Aminopyridines
Antineoplastic Combined Chemotherapy Protocols
Class I Phosphatidylinositol 3-Kinases
Disease Progression
Female
High-Throughput Nucleotide Sequencing
Humans
Middle Aged
Morpholines
Neoplasm Metastasis
Patient Safety
Protein Kinase Inhibitors
Proteomics
Response Evaluation Criteria in Solid Tumors
Survival Rate
Treatment Outcome
Triple Negative Breast Neoplasms

authors with profiles

GORDON B MILLS